SCHEMBL7134359

SCHEMBL7134359

CC(C)(C)OC(=O)COc1cccc2c1S(O)(O)CC2Sc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
HPGD P15428 3/20 0.35
MAPT P10636 3/20 0.35
POLB P06746 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
ACLY P53396 3/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
PTPN1 P18031 1/20 0.32
LMNA P02545 2/20 0.32
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134361 0.90 DDB1 (0.39) DDB1CRBNHPGDMAPTPOLB
SCHEMBL7126274 0.87 ABCB1 (0.41) HPGDMAPTNPSR1PTGDR2ALDH1A1
SCHEMBL7129974 0.84 DDB1 (0.38) DDB1CRBNHPGDMAPTPOLB
SCHEMBL7132507 0.84 SCN9A (0.41) HPGDALDH1A1KDM4EKMT2A
SCHEMBL7131900 0.81 PSEN1 (0.38) DDB1CRBNHPGDMAPTPOLB
SCHEMBL7125689 0.80 PTPN1 (0.40) HPGDMAPTPOLBCYP2C9CYP2C19
SCHEMBL7128728 0.79 ACLY (0.37) DDB1CRBNHPGDMAPTPOLB
SCHEMBL7129978 0.78 DDB1 (0.38) DDB1CRBNHPGDMAPTPOLB
SCHEMBL7131252 0.78 FAAH (0.36) HPGDMAPTCYP2C9CYP2C19NPSR1
SCHEMBL7130136 0.78 SLC6A2 (0.36) MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO DDB1 2087/4885CRBN 811/4885HPGD 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.